Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A naturally occurring nonapeptide produced in the hypothalamus and released by the pituitary gland. Known as the 'bonding hormone' for its role in social bonding, trust, and attachment. Also has established medical uses in obstetrics. Growing interest in intranasal oxytocin for social anxiety, autism spectrum disorder, and relationship enhancement.
A nonapeptide (9 amino acids) first isolated from rabbit cerebral venous blood in 1977. Originally studied for sleep-induction properties, it is now being investigated for opioid withdrawal and chronic insomnia.
Binds to oxytocin receptors throughout the brain and body. In the brain, modulates the limbic system to reduce fear and increase trust and social engagement. Peripherally, stimulates uterine contractions (obstetric use) and milk ejection. Intranasal delivery allows direct access to the brain via the olfactory pathway.
Modulates the sleep-wake cycle through interactions with opioid, serotonin, and other neurotransmitter systems. Reduces the activity of stress-response systems. Mechanism is not fully characterized, but effects appear to be on circadian regulation and stress adaptation.
- Social anxiety and social bonding
- Autism spectrum disorder support (investigational)
- Relationship and intimacy enhancement
- Postpartum bonding
- Labor induction (FDA-approved obstetric use)
- Sleep quality improvement
- Opioid withdrawal support
- Stress and cortisol reduction
- Chronic insomnia
- Narcolepsy (investigational)
- Potential for emotional dependency with frequent use
- May amplify negative social emotions as well as positive ones
- Headaches and nausea
- Intranasal use has limited long-term safety data
- Contraindicated in certain obstetric situations
- Limited human clinical data
- Mechanism not fully understood
- Potential interactions with opioid medications
- Inconsistent results across studies
- Long-term effects unknown
FDA-approved as Pitocin for obstetric use (labor induction, postpartum hemorrhage). Intranasal oxytocin for psychiatric and social indications is investigational — not FDA-approved for these uses. Available through compounding pharmacies with a prescription for off-label intranasal use.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy indications. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
- Delta sleep-inducing peptide (DSIP): a review
1984 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.